Sanofi-Aventis SA (SNY)

REMINDER

Investor Relations Department

Paris: +331.53.77.45.45 – Bridgewater: +1.908.981.5560

Email: IR@sanofi-aventis.com

28/28

REMINDER

Investor Relations Department

Paris: +33 (0)1.53.77.45.45 – Bridgewater: +1.908.981.5560

Email: IR@sanofi-aventis.com

19/19

REMINDER

Investor Relations

Paris : +33 (0)1.53.77.45.45 – New York : +1.212.551.4018

e-mail: IR@sanofi-aventis.com

28/28

15/15

REMINDER

The 3rd quarter 2005 results will be reviewed at 8.00 am (Paris time) by Mr. Hanspeter Spek, Executive Vice-President Pharmaceutical Operations and Mr. Jean-Claude Leroy, Senior Vice-President CFO. The slides will be available on http://www.sanofi-aventis.com. This presentation will be followed by a Q&A session.

22/23

This press release does not constitute an offer to sell or a solicitation of offers to purchase sanofi-aventis shares. The employee share offering will only be carried out in those jurisdictions in which such offering may be made pursuant to a prospectus or registration statement that has been filed with and/or approved by the relevant local authorities, or pursuant to an exemption from the requirement to file or publish a prospectus or registration statement. More generally, the offering will only be made in jurisdictions in which all required local filings and notices have been made and approvals obtained. This press release is not intended for any jurisdiction in which such a prospectus has not been approved or such an exemption is not available, or in which all other required filings and notifications have not been made or approvals obtained.

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words “expect,” “anticipates,” “believes,” “intends,” “estimates,” “plans” and similar expressions. Although sanofi-aventis’ management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in sanofi-aventis’ annual report on Form 20-F for the year ended December 31, 2004. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements. The sanofi-aventis Group conducts its business in the United States through its subsidiaries Sanofi-Synthélabo Inc., Aventis Pharmaceuticals Inc. and Sanofi Pasteur Inc.

23/23

Reminder

Investor Relations Department
Europe Tel: + 33 1 53 77 45 45 US Tel: + 1 212 551 40 18
E-mail : IR@sanofi-aventis.com